dextromethorphan hydrobromide; guaifenesin; naproxen sodium - Profile

What are the generic drug sources for dextromethorphan hydrobromide; guaifenesin; naproxen sodium and what is the scope of freedom to operate?

Dextromethorphan hydrobromide; guaifenesin; naproxen sodium is the generic ingredient in one branded drug marketed by Rb Hlth and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dextromethorphan hydrobromide; guaifenesin; naproxen sodium has seven patent family members in four countries.

Summary for dextromethorphan hydrobromide; guaifenesin; naproxen sodium

International Patents:	7
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dextromethorphan hydrobromide; guaifenesin; naproxen sodium

Constraining patent/regulatory exclusivity:

12,257,218

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for dextromethorphan hydrobromide; guaifenesin; naproxen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rb Hlth	MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM	dextromethorphan hydrobromide; guaifenesin; naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	217338-001	Dec 22, 2025		OTC	Yes	Yes	12,257,218		Y
Rb Hlth	MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM	dextromethorphan hydrobromide; guaifenesin; naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	217338-001	Dec 22, 2025		OTC	Yes	Yes	12,370,189		Y
Rb Hlth	MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM	dextromethorphan hydrobromide; guaifenesin; naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	217338-001	Dec 22, 2025		OTC	Yes	Yes	11,278,506		Y

International Patents for dextromethorphan hydrobromide; guaifenesin; naproxen sodium

Country	Patent Number	Title	Estimated Expiration
United Kingdom	201506755
World Intellectual Property Organization (WIPO)	2017062997
Canada	3001337
European Patent Office	3364955
European Patent Office	3209286

Supplementary Protection Certificates for dextromethorphan hydrobromide; guaifenesin; naproxen sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539166	SPC/GB13/070	United Kingdom		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626
1539166	13C0062	France		PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
1539166	2013/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
1539166	CR 2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
1539166	60/2013	Austria		PRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626

Investment Analysis for Dextromethorphan Hydrobromide, Guaifenesin, and Naproxen Sodium

Last updated: February 20, 2026

This report evaluates the market and fundamental factors influencing the investment potential of three widely used pharmaceutical compounds: dextromethorphan hydrobromide, guaifenesin, and naproxen sodium. It assesses commercial viability, patent landscape, regulatory environment, market dynamics, and competitive positioning.

Market Overview and Therapeutic Context

Dextromethorphan Hydrobromide

Used predominantly as an antitussive agent in over-the-counter cough suppressants. The global market for cough remedies was valued at approximately $7 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 4.1% through 2030. Dextromethorphan constitutes the core active ingredient in many formulations, including Robitussin and Delsym.

Guaifenesin

An expectorant used to loosen mucus in respiratory conditions. The global expectorants market reached about $2.5 billion in 2022, with a CAGR of 3.8%. Guaifenesin is sold both as a standalone product and combined with other active ingredients, in OTC formulations.

Naproxen Sodium

A non-steroidal anti-inflammatory drug (NSAID) used for pain, inflammation, and fever. The NSAID market was valued at $12 billion in 2022 with a CAGR of 4.5%. Naproxen sodium accounts for a significant share, marketed under brands such as Aleve.

Patent and Regulatory Landscape

Compound	Patent Status	Regulatory Approvals	Key Market Entrants
Dextromethorphan Hydrobromide	Expired in key markets (US, EU)	OTC status; FDA, EMA approval	Johnson & Johnson, GSK
Guaifenesin	Expired in US; Limited patent protection	OTC; FDA approval	Johnson & Johnson, Bayer
Naproxen Sodium	Patent expired; formulations protected	OTC and Rx; FDA, EMA approval	Bayer, Aleve (Bayer), Walgreens

Patent expiration for dextromethorphan and guaifenesin has led to a highly competitive market landscape. Naproxen's formulations are still protected in certain delivery forms, though the active is off-patent.

Competitive Dynamics and Market Share

Dextromethorphan Hydrobromide

Dominated by multiple OTC brands with similar formulations. Key manufacturers include Johnson & Johnson, GSK, and private label brands. Market volume is largely driven by OTC sales with low differentiation.

Guaifenesin

High market saturation with generics and store brands. Potential for formulation innovation is limited due to patent expiry. Most sales are driven by price competition.

Naproxen Sodium

More consolidated with leading brands controlling significant market share. Innovation centers on new delivery forms (topical gels, nanoparticles). OTC and Rx segments are both active.

R&D and Innovation Trends

Area	Innovation Focus	Key Factors
Dextromethorphan Hydrobromide	Abuse-deterrent formulations, combination drugs	Regulatory pressure, abuse prevention
Guaifenesin	Combination formulations, novel delivery systems	Market differentiation
Naproxen Sodium	Extended-release formulations, topical versions	Efficacy improvements, safety profiles

Investment in reformulations or combination therapies is limited due to patent expiry. Focus is on optimizing delivery and safety profiles to maintain market share.

Regulatory and Market Drivers

• Increased OTC market penetration in emerging markets.
• Regulatory emphasis on abuse deterrence, especially for dextromethorphan.
• Consumer preference shifts toward natural and multi-symptom remedies.
• Price competition driving consolidation and innovation.

Financial and Investment Considerations

• Lack of patent exclusivity suggests limited pricing power and margin compression.
• Market growth is steady but not rapid; large existing markets.
• Opportunities exist in formulation innovation, especially combining these compounds with new delivery systems.
• Entry barriers are low due to generic availability and OTC status.

Risks and Challenges

• Market saturation diminishes potential for high-margin novel drugs.
• Regulatory risks tied to safety concerns, especially for dextromethorphan abuse issues.
• Price erosion from generics limits profitability.

Strategic Recommendations

• Focus on formulation innovation in delivery systems.
• Explore combination therapies that meet unmet needs or improve safety.
• Monitor regulatory developments, especially regarding abuse deterrence.
• Consider geographic expansion into emerging markets with increasing OTC demand.

Key Takeaways

1. The compounds exhibit mature markets with high generic penetration, limiting potential for large profit margins.
2. Innovation opportunities are primarily in formulation and combination therapies, not core active compounds.
3. Regulatory pressures, especially on dextromethorphan, influence formulation strategies.
4. Market growth remains steady, driven by OTC demand and emerging market expansion.
5. Companies with proprietary delivery systems or unique formulations may maintain competitive advantages.

FAQs

Q1: Are there patent protections available for these compounds?
No. Patents have expired in most regions, resulting in a highly commoditized market landscape.

Q2: What are the regulatory barriers to entering this market?
Low for OTC products but involves compliance with safety and abuse deterrence standards set by FDA and EMA.

Q3: Is there room for innovation in these compounds?
Limited to formulation enhancements, delivery systems, and combination formulations, not the active ingredients themselves.

Q4: How do market dynamics differ globally?
Developed markets are saturated; growth potential exists in emerging markets with increasing OTC access and demand.

Q5: What are the main risks for investors?
Market saturation, pricing pressures, regulatory challenges, and limited differentiation are primary risks.

References

[1] MarketsandMarkets. (2022). Over-the-counter (OTC) Drugs Market. Retrieved from https://www.marketsandmarkets.com
[2] GlobalData. (2022). Respiratory Drugs Report.
[3] USPTO. (2022). Patent Statuses for OTC Active Ingredients.
[4] FDA. (2022). Over-the-Counter Monograph Process.
[5] Statista. (2023). Market size and forecast for NSAIDs.